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We report a case of gastric cancer in a patient with non-cirrhotic hyperammonemia secondary to a spontaneous
portacaval shunt. The patient, a 69-year-old male, had more than 40 years of abdominal discomfort. On gastroscopy,
2.0 × 1.5-cm irregular uplift ulcers were seen on the lesser curvature of the stomach, and tissue biopsy revealed
poorly differentiated adenocarcinoma. His hyperammonemia was found on celiac angiography to be due to the
formation of a spontaneous portacaval shunt. Imaging revealed no evidence of cirrhosis or portal hypertension. The
patient ultimately underwent a distal gastrectomy and gastroduodenal anastomosis; the spontaneous portacaval
shunt was left untreated. Postoperatively, there were no short-term complications such as anastomotic leakage,
stricture, or bleeding, and the patient’s blood ammonia level decreased to within the normal range. Radical gastrectomy
without splenectomy or closure of the abnormal shunt was feasible for the treatment of gastric cancer in a patient with
non-cirrhotic hyperammonemia.
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Hyperammonemia is associated with high perioperative
morbidity and mortality in patients undergoing gastric
surgery. The operative indications are difficult to deter-
mine for gastric cancer patients with hyperammonemia.
We report a case of surgical treatment for gastric cancer
in a patient with hyperammonemia.
Case presentation
A 69-year-old man with a history of hyperammonemia
presented to the First Hospital of China Medical Univer-
sity with more than 40 years of abdominal discomfort.
This discomfort was described as having no regular pat-
tern or relationship to diet and was slightly relieved by
oral omeprazole. He underwent gastroscopy at a local
hospital that revealed 2.0 × 1.5-cm irregular uplift ulcers
in the lesser curvature of the stomach. The tissue was
friable, bled easily, and had a dirty-moss appearance and
surrounding mucosal edema. And, peristalsis had not
been present. Tissue biopsy revealed poorly differenti-
ated adenocarcinoma.* Correspondence: josieon826@sina.cn
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unless otherwise stated.His medical history included hypertension for 20 years
and coronary heart disease for more than 10 years. Two
years earlier, the patient had been diagnosed with a
spontaneous portacaval shunt with recurrent headache
and an extremely elevated blood ammonia concentra-
tion. He had no history of diabetes, chronic hepatitis, or
tuberculosis and no surgical or trauma history.
The patient was in good overall condition. His vital
signs were stable and his weight was stable. His skin and
mucous membranes were not scleral icterus. He had no
liver palms or spider angiomata. His abdomen was flat
and symmetric, without peristaltic wave, or caput medu-
sae. He had normal bowel sounds without succussion
splash or vascular murmur and no abdominal tenderness
or rebound tenderness. No mass was palpated in the
liver or spleen. There was no shifting dullness.
Laboratory examination demonstrated no anemia and
a carbohydrate antigen 19-9 (CA 19-9) of 55.73 U/mL
(reference range 0 to 27 U/mL). The patient’s blood am-
monia concentration was 123 μmol/L, which was signifi-
cantly higher than the upper limit of normal (reference
range 9 to 33 μmol/L). Other laboratory values were
within the normal range.
Enhanced three-dimensional computed tomography
(3D-CT) showed gastric wall thickening, an unevens is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Liu et al. World Journal of Surgical Oncology  (2015) 13:76 Page 2 of 4mucosal surface, and ulcer formation at the gastric
angle. There were clear boundaries between thickened
and normal areas of the gastric wall. The gastric serosal
surface was smooth. Unenhanced CT scan demonstrated
a thickened parietal layer with a value of about 36
Hounsfield units, which increased after enhancement.
There was no lymph node enlargement in the peri-
gastric or peri-aortic areas, including the posterior ab-
dominal wall and inferior vena cava, and no abnormal
soft tissue density in the peritoneum, omentum, or mes-
entery. On unenhanced CT, multiple round hypodensi-
ties were seen in the liver. Color Doppler ultrasound did
not demonstrate any abnormalities in the gallbladder,
spleen, or pancreas. Abdominal aortic CT showed that
the walls of the abdominal aorta, bilateral common iliac
arteries, and bilateral internal iliac arteries were not
smooth, and multiple punctate calcifications were seen
in the local vascular walls. There was no significant lu-
minal narrowing. The celiac trunk and branches of the
superior mesenteric artery, bilateral renal arteries, and
superior mesenteric arteries were normal (Figure 1).
After discussion in the surgical oncology department,
the patient underwent celiac angiography. During the
procedure, we observed an abnormal communication ofFigure 1 Abdominal aortic CT. (A) Abdominal aorta. (B) Right
common iliac artery. (C) Left common iliac artery. (D) Right internal
iliac artery. (E) Left internal iliac artery. (F) Right external iliac artery.
(G) Left external iliac artery. (H) Right renal artery. (I) Left renal artery.the superior mesenteric vein with the spermatic vein,
which demonstrated compensatory enlargement and an
abnormal shunt direction from the portal vein to the su-
perior mesenteric vein, spermatic vein, left renal vein,
and inferior vena cava. After successful puncture of the
right femoral vein using Seldinger technique, a super-
smooth guidewire with a Cobra tip (Terumo Interven-
tional Systems, Somerset, NJ, USA) was advanced to the
left renal vein, then into the portal vein via the abnormal
shunt. Portal vein and superior mesenteric vein angiog-
raphy was performed using a high-pressure syringe, with
smooth delivery of contrast agent. No clear stenosis was
seen (Figure 2). Therefore, this abnormal shunt was con-
sidered congenital condition and no treatment. The pa-
tient was given lactulose 10 g orally twice a day and
ornithine aspartate 15 g intravenous infusion once a day,
for 7 days prior to surgery to reduce blood ammonia. He
also received two water enemas the night before the
operation.
At a multidisciplinary meeting, we discussed performing
interventional embolization of the shunt if ammonia con-
tinued to be elevated after gastrectomy in this elderly pa-
tient with normal liver function and no cirrhosis. The
patient underwent radical subtotal resection of the distal
stomach under general anesthesia without splenectomy or
closure of the abnormal shunt. Intraoperative explorationFigure 2 Celiac angiography. (A) Inferior vena cava. (B) Left renal
vein. (C) Spermatic vein. (D) Superior mesenteric vein. (E) Portal vein.
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body. Postoperative pathology revealed a 3.5 × 3 × 1.5-cm
main focus located primarily in the lesser curvature of the
gastric body. General classification: Borrmann III; histo-
logical type: poorly differentiated adenocarcinoma and sig-
net ring-cell carcinoma; infiltration depth: subepithelial;
growth pattern: diffuse growth; vein thrombosis: none;
lymphatic invasion: none; residual stump: none; lymph
node metastases: none (0/18). The patient recovered well
postoperatively. Blood ammonia was well controlled and
within the normal range (Figure 3). The patient was dis-
charged on postoperative day 12. At 3-month follow-up,
no abnormalities were seen on physical or laboratory
examination. In particular, blood ammonia concentration
continued to be within the normal range.
Discussion
Gastric cancer is one of the most common gastrointes-
tinal cancers worldwide, with a high incidence and
cancer-related mortality [1]; radical gastrectomy remains
the primary cure [2]. Not only hyperammonemia is com-
monly found in patients with liver failure because of the
reduced ability of the liver to synthesize urea, but it is
also seen in patients with portosystemic branch circula-
tion, in which increases in intestinal ammonia have direct
access to the systemic circulation, thus elevating blood
ammonia. Encephalopathy, including recurrent headache,
acute mental status changes, asterixis, tremor, and con-
sciousness, is the main complication of the hyperammone-
mia in patients with and without liver cirrhosis [3]. WeFigure 3 Blood ammonia value changed during hospitalization. The b
the hospital. And, it was delined from 100 to 27 μmol/L during the operationhave reported the case of a 69-year-old man with gastric
cancer and non-cirrhotic hyperammonemia.
To prevent encephalopathy and reduce perioperative
risks during radical gastrectomy, it is important to deter-
mine the etiology of the hyperammonemia preopera-
tively. Ultrasonography was shown to be a reliable and
noninvasive diagnostic method in 90 dogs with hyper-
ammonemia [4]. Ubara et al. reported the use of color
Doppler ultrasonography, in a hyperammonemic patient
without liver function abnormalities, to identify a large
shunt between the left gastric vein and left renal vein
leading to portal flow entering the systemic circulation
via the renal vein [5]. However, color Doppler ultrason-
ography of our patient demonstrated a portal system
without expansion and revealed no abnormal shunt. Ul-
timately, percutaneous angiography revealed an unusual
diversion that was the most likely cause of elevated
blood ammonia.
Following radical gastrectomy, the patient’s blood am-
monia decreased significantly to within the normal
range, where it remained at 3-month follow-up. We be-
lieve this supports the effect of gastric cancer on blood
ammonia levels in our patient without cirrhosis; how-
ever, this will require further study.
After clarifying the source of hyperammonemia, ap-
propriate treatment may not only help control blood
ammonia to prevent hepatic encephalopathy but also
could reduce perioperative risk and extend the lives of
patients with gastric cancer. Takeda et al. reported spon-
taneous portacaval shunts in two patients with gastriclood ammonia value was 123 μmol/L when the patient admitted to
. And, it had a one-time increase postoperative, and then it was normal.
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gastrectomy and end-to-side esophagogastrostomy with
splenectomy, including the closure of the shunt, and the
other underwent a distal gastrectomy with devasculari-
zation around the gastric cardia, including splenectomy,
with preservation of the short gastric vessels [6]. In an-
other report, a 61-year-old woman with gastric cancer
and a large-caliber portohepatic venous shunt under-
went left lateral hepatic segmentectomy and subtotal
gastrectomy with splenectomy [7]. Fenves et al. reported
on five women with no history of liver disease who de-
veloped fatal hyperammonemic encephalopathy after
Roux-en-Y gastric bypass surgery [8]. Our patient also
underwent a distal gastrectomy and gastroduodenal
anastomosis (Billroth I procedure); however, we did not
perform a splenectomy or specific treatment for the
spontaneous portacaval shunt. While the patient had no
history of cirrhosis or portal hypertension, this abnormal
shunt could have been addressed with interventional
embolization if the hyperammonemia had persisted after
gastric resection. Although the patient had an abnormal
shunt, the gastric structure was normal. After the gas-
trectomy, there were no short-term complications of
anastomotic leakage, stricture, or bleeding, and blood
ammonia remained within the normal range, except for
transient increases before the defecation. We believe this
may be a feasible surgical approach in these patients.
Postoperative treatment continues to be important for
gastric cancer patients with hyperammonemia. The pa-
tient may develop distant metastases postoperatively if
the patient has portal vein metastasis and thrombosis,
which may aggravate hyperammonemia and induce en-
cephalopathy [9]; however, postoperative chemotherapy
should not include 5-fluorouracil for these patients. A
number of studies have shown that patients with ad-
vanced gastric cancer who received 5-fluorouracil-based
chemotherapy may develop with mild toxicity, including
hyperammonemia, which may result in hyperammonemia-
related death [10-13]. Subsequent treatment must there-
fore be undertaken with caution.
Conclusions
The most important factor affecting the prognosis for a
hyperammonemia in patients with gastric cancer without
hepatic cirrhosis is a definitive preoperative diagnosis. It is
also important to determine which type of operation
should be performed and to use medications such as oral
lactulose and ornithine aspartate to lower blood ammonia
in high-risk patients. Finally, gastrectomy without splenec-
tomy or closure of the shunt is feasible.
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